ObjectiveTo investigate clinical effect and mechanism by Yupingfeng granules combined with budesonide nasal spray in the treatment of moderate-severe persistent allergic rhinitis (PAR) patients. MethodsA total of 86 patients with moderate-severe persistent allergic rhinitis of non-solid qi deficiency were randomly divided into treatment group and control group, with 43 cases in each group. The treatment group received Yupingfeng granules + budesonide nasal spray for treatment, and the control group received single budesonide nasal spray for treatment. Evaluation of disease condition and related indexes were made before and in 4, 12 weeks after treatment.ResultsBoth groups had obviously lower total scores of symptoms and vital signs after 4 weeks of treatment than those before treatment, and the difference had statistical significance (P<0.05), while there was no statistically significant difference between the two groups (P>0.05). After 12 weeks of treatment, the treatment group had 7 cases with moderate-severe symptoms (16.28%) and the control group had 18 cases with moderate-severe symptoms (41.86%). The treatment group had fewer cases than the control group, and the difference had statistical significance (χ2=6.824,P<0.05). After 4 weeks of treatment, both groups had much lower interleukin (IL)-4 and IL-5 contents in nasal secretion than those before treatment, and their difference had statistical significance (P<0.05), while the difference between the two groups had no statistical significance (P>0.05). After 12 weeks of treatment, the treatment group had obviously lower contents than the control group, and the difference had statistical significance (P<0.05).ConclusionCombination of Yupingfeng granules and budesonide nasal spray shows precisely clinical effect in treating patients with moderate-severe persistent allergic rhinitis of non-solid qi deficiency. This method can provide stable and persistent symptom control period and enhance long-term curative effect of drugs.%目的：探讨在中-重度持续性变应性鼻炎(PAR)患者中应用玉屏风颗粒联合布地奈德鼻喷剂治疗的临床疗效及作用机制。方法86例症属气虚不固的中-重度持续性变应性鼻炎患者,随机分成治疗组和对照组,每组43例。治疗组采用玉屏风颗粒口服+布地奈德鼻喷剂治疗,对照组单纯使用布地奈德鼻喷剂治疗。在治疗前、治疗4周及治疗12周后分别进行病情及相关指标的评估。结果两组患者治疗4周后,症状和体征总分均较治疗前显著下降,差异具有统计学意义(P<0.05),但两组间比较,差异无统计学意义(P>0.05)。治疗12周后,治疗组中-重度症状发作患者7例(16.28%),对照组中-重度症状发作患者18例(41.86%),治疗组少于对照组,差异具有统计学意义(χ2=6.824,P<0.05)。两组患者治疗4周后,鼻腔分泌物中白细胞介素(IL)-4、IL-5含量较治疗前显著降低,差异具有统计学意义(P<0.05),但组间比较差异无统计学意义(P>0.05)。治疗12周后,治疗组显著低于对照组,差异具有统计学意义(P<0.05)。结论玉屏风颗粒联合布地奈德鼻喷剂治疗症属气虚不固的中-重度持续性变应性鼻炎患者临床疗效显著,可获得更加稳定而持久的症状控制期,提高药物远期治疗效果。
展开▼
